Saredutant
Chemical compound
- none
- N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)- 2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide
- 142001-63-6
N
- 104974
- 2111
- 94726
Y
- 720U2QK8I5
- ChEMBL308148
Y
- DTXSID00161923
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- Clc1ccc(cc1Cl)[C@H](CCN3CCC(c2ccccc2)(NC(=O)C)CC3)CN(C(=O)c4ccccc4)C
InChI
- InChI=1S/C31H35Cl2N3O2/c1-23(37)34-31(27-11-7-4-8-12-27)16-19-36(20-17-31)18-15-26(25-13-14-28(32)29(33)21-25)22-35(2)30(38)24-9-5-3-6-10-24/h3-14,21,26H,15-20,22H2,1-2H3,(H,34,37)/t26-/m1/s1
Y
- Key:PGKXDIMONUAMFR-AREMUKBSSA-N
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist.[1] It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.[2]
See also
References
- ^ Hopkins CR (October 2010). "ACS chemical neuroscience molecule spotlight on Saredutant". ACS Chemical Neuroscience. 1 (10): 653–4. doi:10.1021/cn100061r. PMC 3368631. PMID 22776916.
- ^ "Letter to the stockholders of Sanofi-Aventis" (PDF). May 2009. Archived from the original (PDF) on 21 December 2010.
- v
- t
- e
Specific reuptake inhibitors and/or receptor modulators | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
Miscellaneous | |
---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e